In premenopausal women with early-stage estrogen receptor (ER)-positive breast cancer at high risk of disease recurrence, maximal suppression of circulating estradiol using ovarian function suppression and aromatase inhibition improves oncological outcomes compared to standard therapy with tamoxifen, a selective estrogen receptor modulator (1, 2). The gene discussed is CYP19A1; the disease is breast carcinoma.